FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Epithelial Cancer | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer